Skip to content

Study · Randomized controlled trial · n = 6 · 2019

7 results

Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.

Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, Perano SJ, Gagliardi L, Rayner CK, Horowitz M, Couper JJ

Diabetes, obesity & metabolism25 Oct 2018Cited by 40 (Europe PMC)

PMID30259623 (opens in a new tab)DOI10.1111/dom.13544 (opens in a new tab)PepBankPUB-30259623
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced blood glucose AUC versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced blood sugar exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose AUC
    Study

    n = 6

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The primary outcomes, area under the curve over 240 minutes (AUC 240 ) for blood glucose (P < 0.0001) and peak blood glucose (7.65 mM ± 0.34 [mean ± SE] vs 9.53 mM ± 0.63, P < 0.0001), were markedly lower after exenatide than placebo.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced peak blood glucose versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced peak blood sugar versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePeak blood glucose
    Study

    n = 6

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Measurements

    Peak blood glucose
    7.65 mM
    exenatide
    Peak blood glucose
    9.53 mM
    placebo

    Source sentences

    Summary
    The primary outcomes, area under the curve over 240 minutes (AUC 240 ) for blood glucose (P < 0.0001) and peak blood glucose (7.65 mM ± 0.34 [mean ± SE] vs 9.53 mM ± 0.63, P < 0.0001), were markedly lower after exenatide than placebo.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced insulin AUC versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced insulin exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin AUC
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) was also lower after exenatide.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced C-peptide AUC versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced C-peptide exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseC-peptide AUC
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) was also lower after exenatide.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced GLP-1 AUC versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced GLP-1 exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGLP-1 AUC
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) was also lower after exenatide.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide reduced GIP AUC versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide reduced GIP exposure versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGIP AUC
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) was also lower after exenatide.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In young people with CF and IGT, exenatide slowed gastric emptying versus placebo.

    In plain wordsIn young people with CF and IGT, exenatide slowed stomach emptying versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGastric emptying
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    2.5 mcg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Gastric emptying was markedly slower after exenatide, as assessed by time for 10% gastric emptying and peak 13 CO2 excretion.
    2 context sentences
    Summary · context
    Six participants with CF and IGT were studied on 2 days, in a double-blind randomized crossover trial.
    Summary · context
    After overnight fasting, they received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with 13 C octanoate and pancreatic enzyme replacement.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.